FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:734-735 September 2, 1993 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Treatment of histiocytosis X is palliative at best. It includes corticosteroids, alkylating agents, antimetabolites, vinca alkaloids, and irradiation¹. Since 2-chlorodeoxyadenosine, a purine substrate analogue active against lymphoid cancers,² is toxic to monocytes in vitro,³ and since tissue histiocytes are derived from circulating monocytes as they move from the intravascular space to soft tissues, we administered 2-chlorodeoxyadenosine to a patient with histiocytosis X.

A 33-year-old woman had presented at the age of 15 years with polyuria and polydipsia due to diabetes insipidus. Two years later vesiculopustular lesions developed on her gingiva, scalp, and vagina that were histologically . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Egeler, R. M., Favara, B. E., van Meurs, M., Laman, J. D., Claassen, E. (1999). Differential In Situ Cytokine Profiles of Langerhans-Like Cells and T Cells in Langerhans Cell Histiocytosis: Abundant Expression of Cytokines Relevant to Disease and Treatment. Blood 94: 4195-4201 [Abstract] [Full Text]  
• Saven, A., Burian, C. (1999). Cladribine Activity in Adult Langerhans-Cell Histiocytosis. Blood 93: 4125-4130 [Abstract] [Full Text]